Loading...
Please wait, while we are loading the content...
Similar Documents
Disease-modifying drugs in Alzheimer’s disease
| Content Provider | Semantic Scholar |
|---|---|
| Author | Ghezzi, Laura Scarpini, Elio Galimberti, Daniela |
| Copyright Year | 2013 |
| Abstract | Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of dementia. The early stages of AD are characterized by short-term memory loss. Once the disease progresses, patients experience difficulties in sense of direction, oral communication, calculation, ability to learn, and cognitive thinking. The median duration of the disease is 10 years. The pathology is characterized by deposition of amyloid beta peptide (so-called senile plaques) and tau protein in the form of neurofibrillary tangles. Currently, two classes of drugs are licensed by the European Medicines Agency for the treatment of AD, ie, acetylcholinesterase inhibitors for mild to moderate AD, and memantine, an N-methyl-D-aspartate receptor antagonist, for moderate and severe AD. Treatment with acetylcholinesterase inhibitors or memantine aims at slowing progression and controlling symptoms, whereas drugs under development are intended to modify the pathologic steps leading to AD. Herein, we review the clinical features, pharmacologic properties, and cost-effectiveness of the available acetylcholinesterase inhibitors and memantine, and focus on disease-modifying drugs aiming to interfere with the amyloid beta peptide, including vaccination, passive immunization, and tau deposition. |
| Starting Page | 1471 |
| Ending Page | 1479 |
| Page Count | 9 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://www.dovepress.com/getfile.php?fileID=18386 |
| Alternate Webpage(s) | https://air.unimi.it/retrieve/handle/2434/257415/354560/Disease-modifying%20drugs%20in%20Alzheimer's%20disease.pdf |
| PubMed reference number | 24353405 |
| Alternate Webpage(s) | https://doi.org/10.2147/DDDT.S41431 |
| DOI | 10.2147/dddt.s41431 |
| Journal | Drug design, development and therapy |
| Volume Number | 7 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Acetylcholinesterase Inhibitors Alzheimer's Disease Amyloid beta-Peptides Aspartic Acid Biological Markers Cerebrospinal Fluid Class Conflict (Psychology) Dementia Early Diagnosis Memantine Memory Disorders N-Methyl-D-Aspartate Receptors N-Methylaspartate Neurodegenerative Disorders Neurofibrillary degeneration (morphologic abnormality) Passive-Aggressive Personality Disorder Pathologic Processes Patients Pharmacology Progressive Disease Senile Plaques benefit passive immunization procedure |
| Content Type | Text |
| Resource Type | Article |
